Liminatus Pharma, Inc.
LIMN
$0.14
$0.013.85%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -20.73% | 26.10% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 24.51% | 26.10% | |||
| Operating Income | -24.51% | -26.10% | |||
| Income Before Tax | 86.24% | -348.00% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 86.24% | -348.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 86.24% | -348.00% | |||
| EBIT | -24.51% | -26.10% | |||
| EBITDA | -24.52% | -26.13% | |||
| EPS Basic | 89.65% | -346.52% | |||
| Normalized Basic EPS | 15.95% | 57.97% | |||
| EPS Diluted | 89.65% | -346.52% | |||
| Normalized Diluted EPS | 15.95% | 57.97% | |||
| Average Basic Shares Outstanding | 32.83% | 0.35% | |||
| Average Diluted Shares Outstanding | 32.83% | 0.35% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||